International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-2
Original Article
To Determine the Frailty Index Score in Intensive Care Unit and Its Association with Patient Outcomes
 ,
 ,
 ,
Published
April 30, 2024
Abstract

Background: Frailty is a critical determinant of outcomes in older ICU patients, yet its prevalence and impact remain underexplored. This study aimed to assess the frailty distribution using Fried's phenotype and its association with ICU outcomes among older adults.

Methods: A prospective cohort study of 60 ICU patients aged ≥65 was conducted, categorizing patients into frail, pre-frail, and non-frail groups. Data on demographics, clinical characteristics, frailty criteria, morbidity, mortality, and ICU interventions were analyzed.

Results: Frail patients (n=36) were older (78 ± 5.6 years) and had longer ICU stays (6 ± 2.8 days, p=0.032) compared to pre-frail (n=20) and non-frail (n=4) patients. Significant differences in frailty criteria were observed, with weight loss (65%), weakness (70%), and poor endurance (60%) predominantly seen in the frail group (p<0.001 for each). Morbidity events were significantly higher in frail patients (41.7%, p=0.05), with a trend towards higher in-hospital mortality (19.4%, p=0.08) and inotrope requirement (33.3%, p=0.06).

Conclusion: Frailty significantly affects ICU outcomes, with frail patients experiencing longer stays and higher morbidity. These findings highlight the necessity of integrating frailty assessment into ICU care protocols to tailor interventions and potentially improve outcomes for this vulnerable population.

Recommended Articles
Loading Image...
Volume-5, Issue-2
Citations
2315 Views
240 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved